Randomized double-blind trial of treatment of vitiligo: Efficacy of psoralen-UV-A therapy vs narrowband-UV-B therapy

Archives of Dermatology

Volumn 143, Issue 5, 2007, Pages 578-584

  Yones, Sami Sasi ^a   Palmer, Roy A ^a   Garibaldinos, Trish M ^a   Hawk, John L M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BERGAPTEN; METHOXSALEN; PENTADERM; PUVASORALEN; UNCLASSIFIED DRUG;

ADULT; AGED; APPLICATION SITE ERYTHEMA; ARTICLE; BODY SURFACE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; NAUSEA; PHOTOTHERAPY; PRIORITY JOURNAL; PUVA; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SKIN COLOR; SKIN PIGMENTATION; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION; VITILIGO;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PHOTOSENSITIZING AGENTS; PUVA THERAPY; TREATMENT OUTCOME; ULTRAVIOLET THERAPY; VITILIGO;

EID: 34249095105     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.5.578     Document Type: Article

References (26)

1. Papadopoulos L, Bor R, Hawk JLM. Psychology in Relation to Dermatology. London, England: British Psychological Society; 1999:1-363.
2. Whitton ME, Ashcroft DM, Barrett CW, Gonzalez U. Interventions for vitiligo. Cochrane Database Syst Rev. 2006;1:CD003263.
3. Westerhof W, Nieuweboer-Krobotova L. Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. Arch Dermatol. 1997;133:1525-1528.
4. Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol. . 2000;42(2 pt 1):245-253.
5. Scherschun L, Kim JJ, Lim HW. Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo. J Am Acad Dermatol. 2001;44:999-1003.
6. Patel DC, Evans AV, Hawk JL. Topical pseudocatalase mousse and narrowband UVB phototherapy is not effective for vitiligo: an open, single-centre study. Clin Exp Dermatol. 2002;27:641-644.
7. Tjioe M, Gerritsen MJ, Juhlin L, van de Kerkhof PC. Treatment of vitiligo vulgaris with narrow band UVB (311 nm) for one year and the effect of addition of folic acid and vitamin B12. Acta Derm Venereol. 2002;82:369-372.
8. Natta R, Somsak T, Wisuttida T, Laor L. Narrowband ultraviolet B radiation therapy for recalcitrant vitiligo in Asians. J Am Acad Dermatol. 2003;49:473-476.
9. Samson Yashar S, Gielczyk R, Scherschun L, Lim HW. Narrow-band ultraviolet B treatment for vitiligo, pruritus, and inflammatory dermatoses. Photodermatol Photoimmunol Photomed. 2003;19:164-168.
10. Kullavanijaya P, Lim HW. Topical calcipotriene and narrowband ultraviolet B in the treatment of vitiligo. Photodermatol Photoimmunol Photomed. 2004;20:248-251.
11. Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol. 2004;140:677-683.
12. Kanwar AJ, Dogra S. Narrow-band UVB for the treatment of generalized vitiligo in children. Clin Exp Dermatol. 2005;30:332-336.
13. Brazzelli V, Prestinari F, Castello M, et al. Useful treatment of vitiligo in 10 children with UV-B narrowband (311 nm). Pediatr Dermatol. 2005;22:257-261.
14. Chen GY, Hsu MM, Tai HK, et al. Narrow-band UVB treatment of vitiligo in Chinese. J Dermatol. 2005;32:793-800.
15. Ada S, Sahin S, Boztepe G, Karaduman A, Kolemen F. No additional effect of topical calcipotriol on narrow-band UVB phototherapy in patients with generalized vitiligo. Photodermatol Photoimmunol Photomed. 2005;21:79-83.
16. Leone G, Pacifico A, Iacovelli P, Paro VA, Picardo M. Tacalcitol and narrow-band phototherapy in patients with vitiligo. Clin Exp Dermatol. 2006;31:200-205.
17. El Mofty M, Mostafa W, Esmat S, et al. Narrow band Ultraviolet B 311 nm in the treatment of vitiligo: two right-left comparison studies. Photodermatol Photoimmunol Photomed. 2006;22:6-11.
18. Parsad D, Kanwar AJ, Kumar B. Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligo. J Eur Acad Dermatol Venereol. 2006;20:175-177.
19. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210-216.
20. Kwok YK, Anstey AV, Hawk JL. Psoralen photochemotherapy (PUVA) is only moderately effective in widespread vitiligo: a 10-year retrospective study. Clin Exp Dermatol. 2002;27:104-110.
21. Parsad D, Pandhi R, Dogra S, Kumar B. Clinical study of repigmentation patterns with different treatment modalities and their correlation with speed and stability of repigmentation in 352 vitiliginous patches. J Am Acad Dermatol. 2004;50:63-67.
22. Grimes PE. Psoralen photochemotherapy for vitiligo. Clin Dermatol. 1997;15:921-926.
23. Ibbotson SH, Bilsland D, Cox NH, et al; British Association of Dermatologists. An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop Report. Br J Dermatol. 2004;151:283-297.
24. Man I, Dawe RS, Ferguson J, Ibbotson SH. An intraindividual study of the characteristics of erythema induced by bath and oral methoxsalen photochemotherapy and narrowband ultraviolet B. Photochem Photobiol. 2003;78:55-60.
25. British Photodermatology Group. British Photodermatology Group guidelines for PUVA. Br J Dermatol. 1994;130:246-255.
26. Diffey BL. Factors affecting the choice of a ceiling on the number of exposures with TL01 ultraviolet B phototherapy. Br J Dermatol. 2003;149:428-430.